BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kilinç G, Saris A, Ottenhoff THM, Haks MC. Host-directed therapy to combat mycobacterial infections. Immunol Rev 2021;301:62-83. [PMID: 33565103 DOI: 10.1111/imr.12951] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Park EJ, Silwal P, Jo EK. Host-Pathogen Interactions Operative during Mycobacteroides abscessus Infection. Immune Netw 2021;21:e40. [PMID: 35036027 DOI: 10.4110/in.2021.21.e40] [Reference Citation Analysis]
2 Forn-Cuní G, Welvaarts L, Stel FM, van den Hondel CJ, Arentshorst M, Ram A, Meijer AH. Stimulating the autophagic-lysosomal axis enhances host defense against fungal infection in a zebrafish model of invasive Aspergillosis. Autophagy 2022;:1-14. [PMID: 35775203 DOI: 10.1080/15548627.2022.2090727] [Reference Citation Analysis]
3 Kilinç G, Walburg KV, Franken KLMC, Valkenburg ML, Aubry A, Haks MC, Saris A, Ottenhoff THM. Development of Human Cell-Based In Vitro Infection Models to Determine the Intracellular Survival of Mycobacterium avium. Front Cell Infect Microbiol 2022;12:872361. [DOI: 10.3389/fcimb.2022.872361] [Reference Citation Analysis]
4 Heemskerk MT, Korbee CJ, Esselink JJ, Dos Santos CC, van Veen S, Gordijn IF, Vrieling F, Walburg KV, Engele CG, Dijkman K, Wilson L, Verreck FAW, Ottenhoff THM, Haks MC. Repurposing diphenylbutylpiperidine-class antipsychotic drugs for host-directed therapy of Mycobacterium tuberculosis and Salmonella enterica infections. Sci Rep 2021;11:19634. [PMID: 34608194 DOI: 10.1038/s41598-021-98980-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Park HE, Lee W, Shin MK, Shin SJ. Understanding the Reciprocal Interplay Between Antibiotics and Host Immune System: How Can We Improve the Anti-Mycobacterial Activity of Current Drugs to Better Control Tuberculosis? Front Immunol 2021;12:703060. [PMID: 34262571 DOI: 10.3389/fimmu.2021.703060] [Reference Citation Analysis]
6 Wu X, Jin S, Ding C, Wang Y, He D, Liu Y. Mesenchymal Stem Cell-Derived Exosome Therapy of Microbial Diseases: From Bench to Bed. Front Microbiol 2021;12:804813. [PMID: 35046923 DOI: 10.3389/fmicb.2021.804813] [Reference Citation Analysis]
7 Silwal P, Kim IS, Jo EK. Autophagy and Host Defense in Nontuberculous Mycobacterial Infection. Front Immunol 2021;12:728742. [PMID: 34552591 DOI: 10.3389/fimmu.2021.728742] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Khoza LJ, Kumar P, Dube A, Demana PH, Choonara YE. Insights into Innovative Therapeutics for Drug-Resistant Tuberculosis: Host-Directed Therapy and Autophagy Inducing Modified Nanoparticles. International Journal of Pharmaceutics 2022. [DOI: 10.1016/j.ijpharm.2022.121893] [Reference Citation Analysis]
9 Jagannath C, McBride JW, Vergne I. Editorial: The Autophagy Pathway: Bacterial Pathogen Immunity and Evasion. Front Immunol 2021;12:768935. [PMID: 34650572 DOI: 10.3389/fimmu.2021.768935] [Reference Citation Analysis]
10 Mehta K, Spaink HP, Ottenhoff THM, van der Graaf PH, van Hasselt JGC. Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches. Trends Pharmacol Sci 2021:S0165-6147(21)00233-9. [PMID: 34916092 DOI: 10.1016/j.tips.2021.11.016] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Kumar K, Kon OM. Personalised Medicine for Tuberculosis and Non-Tuberculous Mycobacterial Pulmonary Disease. Microorganisms 2021;9:2220. [PMID: 34835346 DOI: 10.3390/microorganisms9112220] [Reference Citation Analysis]
12 Kim YJ, Lee JY, Lee JJ, Jeon SM, Silwal P, Kim IS, Kim HJ, Park CR, Chung C, Han JE, Choi JW, Tak EJ, Yoo JH, Jeong SW, Kim DY, Ketphan W, Kim SY, Jhun BW, Whang J, Kim JM, Eoh H, Bae JW, Jo EK. Arginine-mediated gut microbiome remodeling promotes host pulmonary immune defense against nontuberculous mycobacterial infection. Gut Microbes 2022;14:2073132. [PMID: 35579969 DOI: 10.1080/19490976.2022.2073132] [Reference Citation Analysis]
13 Kilinç G, Saris A, Ottenhoff THM, Haks MC. Host-directed therapy to combat mycobacterial infections. Immunol Rev 2021;301:62-83. [PMID: 33565103 DOI: 10.1111/imr.12951] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
14 Perveen S, Kumari D, Singh K, Sharma R. Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance. Eur J Med Chem 2022;229:114066. [PMID: 34973508 DOI: 10.1016/j.ejmech.2021.114066] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
15 Varela M, Meijer AH. A fresh look at mycobacterial pathogenicity with the zebrafish host model. Mol Microbiol 2021. [PMID: 34714579 DOI: 10.1111/mmi.14838] [Reference Citation Analysis]
16 Afriyie-Asante A, Dabla A, Dagenais A, Berton S, Smyth R, Sun J. Mycobacterium tuberculosis Exploits Focal Adhesion Kinase to Induce Necrotic Cell Death and Inhibit Reactive Oxygen Species Production. Front Immunol 2021;12:742370. [PMID: 34745115 DOI: 10.3389/fimmu.2021.742370] [Reference Citation Analysis]